Adalimumab clinical trials, in English

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.

NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf

Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.

NCT03414502 · Official ClinicalTrials.gov record · University of Nebraska

This is a randomly assigned compared with a dummy treatment trial in Crohn's disease patients before initiation of anti-tumor necrosis factor-α (anti-TNF) therapy that aims to test the effect of a pre-treatment short course of azithromycin therapy on immunogenicity

NCT05599347 · Official ClinicalTrials.gov record · Rambam Health Care Campus

There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor \[TNF\] alpha, anti-integrin, and anti-interleukin \[IL\]-23 targeted agents. The purpose of this trial is to determine which of these three classes of biologics results in the highest percentage of patients with small bowel (ileal) Crohn's disease entering into endoscopic remission without needing corticosteroids at 1 year.

NCT05928039 · Official ClinicalTrials.gov record · University of Calgary

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.

NCT06100744 · Official ClinicalTrials.gov record · AbbVie

A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy. The optimal intervention in patients with secondary loss-of-response (LOR) is still poorly defined, as there are still scant data on how best to choose the next intervention from among dose-intensification, switch to another anti-TNF or switch out of the anti-TNF class.

NCT06180382 · Official ClinicalTrials.gov record · Centre Hospitalier Universitaire de Saint Etienne

This study aims to conduct a randomly assigned controlled trial to compare the how well it works and safety of Baricitinib and Adalimumab (ADA) in the treatment of refractory intestinal Behçet's Syndrome (BS). The objective is to demonstrate if Baricitinib is non-inferior to ADA in controlling BS inflammation, reducing BS recurrence， alleviating gastrointestinal symptoms and promoting intestinal mucosal healing.

NCT06849908 · Official ClinicalTrials.gov record · Peking Union Medical College Hospital

Open label pragmatic two-stage non-randomly assigned trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).

NCT06941376 · Official ClinicalTrials.gov record · University of Pennsylvania

This is a phase 2 study to assess the ability of adalimumab as compared to dummy treatment (placebo) to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Disease Related Pattern (PDRP) will be assessed using change in 18-flurodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging.

NCT06996652 · Official ClinicalTrials.gov record · Yale University

This multi-center randomly assigned controlled trial will assess the safety and how well it works of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

NCT07061574 · Official ClinicalTrials.gov record · City of Hope Medical Center

This study wants to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

NCT07138898 · Official ClinicalTrials.gov record · NYU Langone Health

The main purpose of this study is to assess the how well it works of multiple dosing regimens of LAD191 compared to dummy treatment (placebo) in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.

NCT07151937 · Official ClinicalTrials.gov record · Almirall, S.A.

This watch-and-measure (no experimental treatment required) study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment.

NCT07166315 · Official ClinicalTrials.gov record · Adelphi Real World

This is a multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel, dummy treatment (placebo)- and active comparator- controlled clinical study conducted in patients with moderately to severely active RA and an inadequate response to at least one DMARD, designed to assess the how well it works and safety of GenSci120 injection in this patient population. The study consists of a screening period (≤ 4 weeks), a compared with a dummy treatment treatment period (14 weeks), an extension treatment period (14 weeks), and a follow-up period (10 weeks), with a total of 17 scheduled visits.

NCT07423533 · Official ClinicalTrials.gov record · Changchun GeneScience Pharmaceutical Co., Ltd.

Investigators hypothesize that TNFi is superior to SC MTX in preventing structural damage in early, treatment-naïve PsA, assessed using HR-pQCT. The study aims to ascertain: \- The effect of SC MTX and TNFi (adalimumab biosimilar) on erosion and enthesiophyte progression in early PsA by HR-pQCT.

NCT07486843 · Official ClinicalTrials.gov record · Chinese University of Hong Kong

Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or relapsing disease.

NCT07491913 · Official ClinicalTrials.gov record · Marmara University

This multicenter, randomly assigned, controlled trial aims to measure the how well it works and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared with TNFi dose intensification in patients with moderate-to-severe Crohn's disease who have a suboptimal response to standard-dose TNFi therapy. Eligible participants are adults with active Crohn's disease receiving standard-dose infliximab or adalimumab who remain inadequately controlled despite ongoing treatment.

NCT07510191 · Official ClinicalTrials.gov record · Sixth Affiliated Hospital, Sun Yat-sen University

Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections (biologics) or a liquid-only diet using specialised milkshakes.

NCT07522528 · Official ClinicalTrials.gov record · University of Glasgow

This study is a real - world clinical research of adalimumab. The project plans to enroll 30 subjects, aiming to measure the incidence of serious side effects (SAEs) within 12, 26, and 52 weeks after treatment; as well as the incidence of side effects (AEs), adverse drug reactions (ADRs), side effects of special interest (AESIs), and serious ADRs at 12, 26, and 52 weeks after treatment.

NCT07564505 · Official ClinicalTrials.gov record · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study is a randomly assigned, open-label, controlled, multicenter Phase II trial conducted in patients with advanced HER2-positive breast cancer, aimed at evaluating the how well it works and safety of paclitaxel polymer micelles for injection combined with trastuzumab and adalimumab versus the paclitaxel-based regimen combined with trastuzumab as first-line treatment. Eligible subjects with histologically or cytologically confirmed advanced HER2-positive breast cancer were enrolled after obtaining informed consent.

NCT07581795 · Official ClinicalTrials.gov record · Fudan University

This study aims to systematically measure the safety and how well it works of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.

NCT07595770 · Official ClinicalTrials.gov record · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

To explore the how well it works and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer

NCT07622771 · Official ClinicalTrials.gov record · Sun Yat-sen University

This study is a real-world clinical research on adalimumab. The safety and how well it works of adalimumab injection for adult non-infectious uveitis are being investigated.

NCT07663331 · Official ClinicalTrials.gov record · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This is a post-marketing real-world study designed to measure the how well it works and safety of Tabellvi® (Adalimumab Injection) in Chinese adult subjects with moderate to severe active Crohn's disease via a single-arm trial. A total of 50 subjects are planned to be enrolled.

NCT07663526 · Official ClinicalTrials.gov record · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This retrospective cohort study aims to compare the how well it works of different biologics in preventing postoperative endoscopic recurrence in Crohn's disease (CD). It plans to include 198 adult patients who underwent bowel resection and initiated prophylactic biologic therapy between January 1, 2015, and April 1, 2025.

NCT07694674 · Official ClinicalTrials.gov record · Shanghai 10th People's Hospital

This is a proof-of-concept study to see if antibodies (guselkumab and adalimumab) delivered directly to the colon can enter the systemic circulation. The study endpoints chosen for this study are commonly used for evaluating the safety, tolerability, and PK of single doses of IPs.

NCT07788807 · Official ClinicalTrials.gov record · Surmount Services, Inc.

The goal of this clinical trial is to learn if the anti-inflammatory medication adalimumab improves depressive symptoms in adults with Major Depressive Disorder (major depression) who are already taking the anti-depressant medication Lexapro (escitalopram). The main questions it aims to answer are: 1.

NCT07845604 · Official ClinicalTrials.gov record · Daniel Moriarity